{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:20:07Z","timestamp":1787761207919,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013405","name":"Rijksdienst voor Ondernemend Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bvth.2026.100176","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:26:55Z","timestamp":1779812815000},"page":"100176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111"],"prefix":"10.1016","volume":"3","author":[{"given":"Edwin","family":"Spaans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3133-5152","authenticated-orcid":false,"given":"Denisa","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Beyrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-5088","authenticated-orcid":false,"given":"Jules A. A. C.","family":"Heuberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-9139","authenticated-orcid":false,"given":"Alex","family":"Zwiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-7966","authenticated-orcid":false,"given":"Kamran","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost C. M.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-2647","authenticated-orcid":false,"given":"Stephan L. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bvth.2026.100176_bib1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00415-019-09572-x","article-title":"Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysis","volume":"268","author":"Cheng","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.bvth.2026.100176_bib2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"issue":"suppl 3","key":"10.1016\/j.bvth.2026.100176_bib3","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"issue":"1 suppl 1","key":"10.1016\/j.bvth.2026.100176_bib4","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1053\/j.seminhematol.2005.11.023","article-title":"New anti-thrombotic agents: emphasis on hemorrhagic complications and their management","volume":"43","author":"Ng","year":"2006","journal-title":"Semin Hematol"},{"issue":"suppl","key":"10.1016\/j.bvth.2026.100176_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2014.8.paradigm","article-title":"Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage","volume":"121","author":"Le Roux","year":"2014","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.bvth.2026.100176_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","article-title":"Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis","volume":"9","author":"van Asch","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100176_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11739-007-0009-y","article-title":"Intracerebral haemorrhage: an often neglected medical emergency","volume":"2","author":"Marietta","year":"2007","journal-title":"Intern Emerg Med"},{"issue":"8","key":"10.1016\/j.bvth.2026.100176_bib8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1474-4422(12)70104-7","article-title":"Intracerebral haemorrhage: mechanisms of injury and therapeutic targets","volume":"11","author":"Keep","year":"2012","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.bvth.2026.100176_bib9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/STROKEAHA.120.032550","article-title":"Intracerebral hemorrhage incidence, mortality, and association with oral anticoagulation use: a population study","volume":"52","author":"Fernando","year":"2021","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.bvth.2026.100176_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ACO.0000000000000697","article-title":"Reversing anticoagulation in the hemorrhaging patient","volume":"32","author":"Treml","year":"2019","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.bvth.2026.100176_bib11","article-title":"Urgent reversal of vitamin K antagonists","volume":"360","author":"Hunt","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.bvth.2026.100176_bib12","article-title":"Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-\u03b1, protamine)","author":"Bekka","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bvth.2026.100176_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.bvth.2026.100176_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.bvth.2026.100176_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2023.05.003","article-title":"OKL-1111, a modified cyclodextrin as a potential universal reversal agent for anticoagulants","volume":"227","author":"Meijers","year":"2023","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.bvth.2026.100176_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/ijms20040899","article-title":"A novel biomarker for acute kidney injury, Vanin-1, for obstructive nephropathy: a prospective cohort pilot study","volume":"20","author":"Washino","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bvth.2026.100176_bib17","article-title":"Qualification of Composite Measure of 6 Urinary Biomarkers to Aid in Detection of Kidney Tubular Injury in Phase 1 Trials of Healthy Volunteers","year":"2018","journal-title":"US Food and Drug Administration"},{"key":"10.1016\/j.bvth.2026.100176_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cca.2014.08.039","article-title":"Biomarkers of renal function, which and when?","volume":"438","author":"Wasung","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.bvth.2026.100176_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","article-title":"Biomarkers of drug-induced kidney toxicity","volume":"41","author":"Griffin","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"12","key":"10.1016\/j.bvth.2026.100176_bib20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jth.13857","article-title":"Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations","volume":"15","author":"Jaffer","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bvth.2026.100176_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-0716-3175-1_23","article-title":"Ecarin-based methods for measuring thrombin inhibitors","volume":"2663","author":"Gosselin","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100176_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00001721-199102000-00019","article-title":"Development of a chromogenic substrate assay for the determination of hirudin in plasma","volume":"2","author":"Spannagl","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.bvth.2026.100176_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rth2.12029","article-title":"Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study","volume":"1","author":"Yasaka","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"21","key":"10.1016\/j.bvth.2026.100176_bib24","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bvth.2026.100176_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bja.2018.05.057","article-title":"Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers","volume":"121","author":"de Kam","year":"2018","journal-title":"Br J Anaesth"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:54Z","timestamp":1787758014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950327226000410"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100176","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100176"}}